SVRA Savara Corp: רווח למניה בשנים עשר החודשים האחרונים

The future of Savara Inc. (SVRA) depends on the US regulatory approval of molgramostim, which creates significant commercial uncertainty. The trailing 12-month net income per share trend confirms these expectations, with the metric settling at -0.61. Savara Inc. (SVRA) specializes in orphan lung drugs, establishing an exclusive therapy system for alveolar proteinosis for patients and clinics.

For Savara Inc., whose operations focus on developing biopharmaceuticals for rare pulmonary pathologies, the trend in rolling net income per share reflects the efficiency of deployed capital. This indicator is calculated by dividing total annual profit by the number of shares outstanding, allowing investors to assess the business's actual ability to generate cash flow per share.